Phosphoinositide-3-kinase (PI3 kinase, Human)

• Description:

  Phosphoinositide-3-kinase (PI3 kinase, Human)_x000D_ Catalog number: B2010514_x000D_ Lot number: Batch Dependent_x000D_ Expiration Date: Batch dependent_x000D_ Amount: 20 ug_x000D_ Molecular Weight or Concentration: 129/88 kDa_x000D_ Supplied as: Solution_x000D_ Applications: molecular tool for the study of enzyme kinetics_x000D_ Storage: ˆ’20°C_x000D_ Keywords: Phosphoinositide-3-kinase, catalytic, alpha, PIK3CA, PtdIns-3-kinase p110_x000D_ Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ References:_x000D_ 1: Choi S, Houdek X, Anderson RA. Phosphoinositide 3-kinase pathways and_x000D_ autophagy require phosphatidylinositol phosphate kinases. Adv Biol Regul. 2018_x000D_ May;68:31-38. ._x000D_ _x000D_ 2: Ramazzotti G, Ratti S, Fiume R, Follo MY, Billi AM, Rusciano I, Owusu Obeng_x000D_ E, Manzoli L, Cocco L, Faenza I. Phosphoinositide 3 Kinase Signaling in Human_x000D_ Stem Cells from Reprogramming to Differentiation: A Tale in Cytoplasmic and_x000D_ Nuclear Compartments. Int J Mol Sci. 2019 Apr 24;20(8):2026._x000D_ _x000D_ 3: Bi Y, Zhang Y, Ren J. Phosphoinositide 3-kinase therapy in diabetic_x000D_ cardiomyopathy: unravelling an enigma. Am J Physiol Heart Circ Physiol. 2020 May_x000D_ 1;318(5):H1029-H1031._x000D_ _x000D_ 4: Chin CK, Nastoupil LJ. Novel Agents Beyond Immunomodulatory Agents and_x000D_ Phosphoinositide-3-Kinase for Follicular Lymphoma. Hematol Oncol Clin North Am._x000D_ 2020 Aug;34(4):743-756._x000D_ _x000D_ 5: Maffucci T, Falasca M. Inositol Polyphosphate-Based Compounds as Inhibitors_x000D_ of Phosphoinositide 3-Kinase-Dependent Signaling. Int J Mol Sci. 2020 Sep_x000D_ 29;21(19):7198._x000D_ _x000D_ 6: Condliffe AM, Chandra A. Respiratory Manifestations of the Activated_x000D_ Phosphoinositide 3-Kinase Delta Syndrome. Front Immunol. 2018 Mar 5;9:338._x000D_ _x000D_ 7: Mazloumi Gavgani F, Smith Arnesen V, Jacobsen RG, Krakstad C, Hoivik EA,_x000D_ Lewis AE. Class I Phosphoinositide 3-Kinase PIK3CA/p110α and_x000D_ PIK3CB/p110β Isoforms in Endometrial Cancer. Int J Mol Sci. 2018 Dec_x000D_ 7;19(12):3931._x000D_ _x000D_ 8: Tang LA, Dixon BN, Maples KT, Poppiti KM, Peterson TJ. Current and_x000D_ Investigational Agents Targeting the Phosphoinositide 3-Kinase Pathway._x000D_ Pharmacotherapy. 2018 Oct;38(10):1058-1067._x000D_ _x000D_ 9: Qiu X, Tian Y, Liang Z, Sun Y, Li Z, Bian J. Recent discovery of_x000D_ phosphoinositide 3-kinase γ inhibitors for the treatment of immune diseases and_x000D_ cancers. Future Med Chem. 2019 Aug;11(16):2151-2169._x000D_ 10: Hurley JH, Young LN. Mechanisms of Autophagy Initiation. Annu Rev Biochem._x000D_ 2017 Jun 20;86:225-244._x000D_ _x000D_ Products Related to Phosphoinositide-3-kinase (PI3 kinase, Human) : Enzymes

• Short Description:

  Catalog Number: B2010514 (20 ug)_x000D_ Phosphoinositide-3-kinase (PI3 kinase, Human) is a highly pure complex of full-length human p110 and recombinant full length, human p85α. This product has been used as molecular tool for the study of enzyme kinetics. It has also been used in a wide array of other biochemical and immunological applications. Custom bulk amounts of this product are available upon request._x000D_ _x000D_

• Weight:

  0.15

• Length:

  2

• Width:

  0.5

• Height :

  0.5